A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity

Documenti analoghi

• Real‐life use of liraglutide 3 mg in obesity management: The SAX‐RL study
  di: Marc Goëau‐Brissonnière, et al.
  Pubblicazione: (2024)
• Nutritional and functional outcomes in trials of nutrient‐stimulated hormone‐based therapy—A systematic mapping review
  di: Sébastien Czernichow, et al.
  Pubblicazione: (2025)
• The safety of semaglutide in patients with depression and obesity
  di: Ziyi Yang, et al.
  Pubblicazione: (2024)
• Response to “The safety of semaglutide in patients with depression and obesity”
  di: Robert F. Kushner, et al.
  Pubblicazione: (2024)
• Identification and functional validation of rare coding variants in genes linked to monogenic obesity
  di: Çiğdem Köroğlu, et al.
  Pubblicazione: (2024)